XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash flows from operating activities:    
Net loss $ (92,524) $ (96,725)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,461 4,838
Amortization of acquired intangible assets 6,952 841
(Gain) loss on disposal of property and equipment (275) 135
Share-based compensation expense 19,794 16,419
Change in fair value of note hedge warrants 50,831 36,221
Change in fair value of convertible note hedges (51,338) (39,359)
Write-down of commercial supply and inventory to net realizable value and loss on non-cancellable purchase commitments 1,836 96
Write-down of excess non-cancellable ZURAMPIC and DUZALLO sample purchase commitments 390 1,353
Gain on facility subleases   (1,579)
Accretion of discount/premium on investment securities (138) 111
Non-cash interest expense 8,591 7,849
Non-cash change in fair value of contingent consideration 2,474 8,547
Loss on extinguishment of debt   2,009
Changes in assets and liabilities:    
Accounts receivable and related party accounts receivable 1,638 4,497
Prepaid expenses and other current assets (9,373) 703
Inventory, net (992) 1,081
Other assets 99 246
Accounts payable, related party accounts payable and accrued expenses 6,276 (5,345)
Accrued research and development costs (1,935) 517
Deferred revenue   225
Deferred rent 656 (2,977)
Net cash used in operating activities (53,577) (60,297)
Cash flows from investing activities:    
Purchases of available-for-sale securities (2,491) (90,706)
Sales and maturities of available-for-sale securities 62,512 251,027
Purchases of property and equipment (3,200) (1,746)
Proceeds from sale of property and equipment 272 79
Net cash provided by investing activities 57,093 158,654
Cash flows from financing activities:    
Proceeds from issuance of 2026 Notes, net of discount to lender   146,250
Costs associated with issuance of 2026 Notes   (235)
Proceeds from exercise of stock options and employee stock purchase plan 19,044 18,473
Payments on capital leases (1,510) (1,593)
Principal payments on PhaRMA notes   (134,258)
Payments on contingent purchase price consideration (121) (56)
Net cash provided by financing activities 17,413 28,581
Net increase in cash, cash equivalents and restricted cash 20,929 126,938
Cash, cash equivalents and restricted cash, beginning of period 132,792 62,251
Cash, cash equivalents and restricted cash, end of period 153,721 189,189
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets    
Cash and cash equivalents 145,415 182,132
Restricted cash 8,306 7,057
Total Cash, cash equivalents, and restricted cash $ 132,792 $ 62,251